Pitman S W, Miller D, Weichselbaum R
Laryngoscope. 1978 Apr;88(4):632-8. doi: 10.1002/lary.1978.88.4.632.
Our initial experience with weekly high dose methotrexate with leucovorin rescue (MTX-LCV), in advanced recurrent or metastatic squamous cell carcinoma of the head and neck with a 77% tumor response rate and high therapeutic index, prompted a trial of MTX-LCV as initial adjuvant therapy in high risk nonmetastatic patients. Results in 11 patients are presented and confirm the high response rate to MTX-LCV and the low incidence of myelotoxicity and mucositis, when concurrent urinary alkalinization is employed. Initial MTX-LCV administrations has not compromised subsequent optimum aggressive combinations of surgery and radiation therapy. Cytoreduction with MTX-LCV may be safely used initially in combined therapy for high risk squamous cell carcinoma of the head and neck.
我们对每周一次大剂量甲氨蝶呤联合亚叶酸钙解救疗法（MTX-LCV）用于晚期复发或转移性头颈部鳞状细胞癌的初步经验显示，肿瘤缓解率为77%，治疗指数高，这促使我们开展一项试验，将MTX-LCV作为高危非转移性患者的初始辅助治疗。本文介绍了11例患者的结果，证实了MTX-LCV的高缓解率以及在同时进行尿液碱化时骨髓毒性和粘膜炎的低发生率。初始MTX-LCV给药并未影响后续手术和放疗的最佳积极联合治疗。MTX-LCV进行细胞减灭术可安全地最初用于高危头颈部鳞状细胞癌的联合治疗。
